Our current research focuses are the followings:
- Exploring nuclear receptor (NR) sub-family members, such as the retinoid receptor-related receptors (RORs)/NR1Fs, as novel therapeutic targets for advanced cancers (e.g. mCRPC);
- Exploring key epigenetic regulators including the histone demethylases (e.g. KDM4s) and bromodomain proteins (e.g. ANCCA/ATAD2) as novel therapeutic targets for cancer;
- Elucidating the functional mechanisms of key epigenetic regulators and nuclear receptors in tumorigenesis and therapeutic resistance;
- Developing biomarkers for guiding effective targeted therapies.